yttrium citrate profile

Yttrium citrate is an inorganic compound with the formula Y(C6H5O7)·xH2O. It is a white solid that is soluble in water. It is synthesized by reacting yttrium hydroxide or yttrium oxide with citric acid. Yttrium citrate has been studied for its potential applications in medicine, including as a contrast agent for magnetic resonance imaging (MRI), as a drug delivery vehicle, and as a potential treatment for cancer. It has also been investigated for its use in the production of ceramics and other materials. The compound's importance stems from the unique properties of yttrium, a rare earth element, which has potential applications in various fields. Research into yttrium citrate focuses on exploring its potential as a therapeutic agent and its uses in advanced materials.'

yttrium citrate: RN given refers to unlabeled tri-Na salt; RN for yttrium-90 citrate not in Chemline 8/85 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	45566
MeSH ID	M0133344

Synonym
yttrium citrate
citric acid, yttrium salt (3:1)
63938-20-5
unii-9l31h05vp4
yttrium tricitrate
yttrium tris(3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate)
2-(carboxymethyl)-2,4-dihydroxy-4-oxobutanoate, yttrium(3+)
yttrium(3+) ion tris(3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate)
1,2,3-propanetricarboxylic acid, 2-hydroxy-, yttrium(3+) salt (3:1)
9L31H05VP4 ,
18404-01-8
Q27272690
2-(carboxymethyl)-2,4-dihydroxy-4-oxobutanoate;yttrium(3+)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (11.76)	18.7374
1990's	5 (29.41)	18.2507
2000's	6 (35.29)	29.6817
2010's	4 (23.53)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	7 (33.33%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (4.76%)	0.25%
Other	13 (61.90%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	3.45	1	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2.06	1	0
(ethylenedinitrilo)-tetramethylenephosphonic acid (ethylenedinitrilo)-tetramethylenephosphonic acid: structure; RN given refers to parent cpd	1.98	1	0
triamcinolone hexacetonide triamcinolone hexacetonide: structure	3.45	1	1	corticosteroid hormone
yttrium Yttrium: An element of the rare earth family of metals. It has the atomic symbol Y, atomic number 39, and atomic weight 88.91. In conjunction with other rare earths, yttrium is used as a phosphor in television receivers and is a component of the yttrium-aluminum garnet (YAG) lasers.	2.37	2	0	d-block element atom; rare earth metal atom; scandium group element atom
yttrium radioisotopes Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.	6.56	10	2
yttrium ethylenediaminetetra(methylenephosphonic acid) yttrium ethylenediaminetetra(methylenephosphonic acid): used in radiotherapy of leukemia	1.99	1	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	1.99	1	0	divalent inorganic anion; phosphite ion
technetium tc 99m medronate Technetium Tc 99m Medronate: A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms.	3.42	1	1

Condition	Relationship Strength	Studies	Trials
Osteoarthritis of Knee [description not available]	2.21	1	0
Plica Syndrome [description not available]	3.31	6	0
Adverse Effects, Long Term [description not available]	2.21	1	0
Synovitis Inflammation of the SYNOVIAL MEMBRANE.	3.31	6	0
Osteoarthritis, Knee Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)	2.21	1	0
Cancer of Liver [description not available]	5.3	2	2
Liver Neoplasms Tumors or cancer of the LIVER.	5.3	2	2
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	3.43	1	1
Christmas Disease [description not available]	2.06	1	0
Autosomal Hemophilia A [description not available]	2.74	3	0
Angiohemophilia [description not available]	2.06	1	0
Hemarthrosis Bleeding into the joints. It may arise from trauma or spontaneously in patients with hemophilia.	2.47	2	0
Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)	2.06	1	0
Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.	2.74	3	0
von Willebrand Diseases Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.	2.06	1	0
Polyarthritis [description not available]	3.45	1	1
Rheumatoid Arthritis [description not available]	4.4	2	2
Arthritis Acute or chronic inflammation of JOINTS.	3.45	1	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	4.4	2	2
Joint Pain [description not available]	2.06	1	0
Arthralgia Pain in the joint.	2.06	1	0
Abnormalities, Autosome [description not available]	2.43	2	0
Benign Neoplasms [description not available]	4.33	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.33	1	1
Bechterew Syndrome [description not available]	3.42	1	1
Spondylarthropathies Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.	3.42	1	1
Complication, Postoperative [description not available]	2.03	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	2.03	1	0
B16 Melanoma [description not available]	1.98	1	0
Experimental Mammary Neoplasms [description not available]	1.98	1	0
Bone Cancer [description not available]	2.39	2	0
Breast Cancer [description not available]	1.98	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.39	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.98	1	0
Cancer of Prostate [description not available]	1.99	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1.99	1	0
Experimental Radiation Injuries [description not available]	1.99	1	0
Experimental Neoplasms [description not available]	1.98	1	0
Carcinosarcoma A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)	1.98	1	0

yttrium citrate

Description

Cross-References

Synonyms (13)

Research

Studies (17)

Market Indicators

Research Demand Index: 16.51

Study Types